News

The deal, which is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company, offers PatientsLikeMe the opportunity to expand its patient network in oncology. PatientsLikeMe co-founder

According to previous Phase II clinical trials, onapristone is shown to exhibit anti-tumour activity in patients with breast cancer. The pre-clinical testing has demonstrated that onapristone had blocked

Pursuant to the terms of the agreement, Shape Pharma will be acquired by TetraLogic Pharma for an upfront cash payment of $13m. TetraLogic will also be responsible for

Under the co-production partnership agreements, Pacira and Patheon will collaborate to construct dedicated Exparel manufacturing suites in Patheon’s specialty sterile manufacturing facility in Swindon. The first additional Exparel

If the same marketing-authorization application is received in parallel by EMA and TGA, the two regulators have the possibility of scientific exchange to facilitate the evaluation of the

vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescription prenatal multivitamin and is the first to contain Folmax, FePlus, and pur-DHA. TherapeuticsMD chief marketing officer

The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics that the company believes are critical for achieving ‘drug-like’ properties in siRNA, the molecules that mediate RNAi.

According to the company, data submitted in the NDAs support the use of DCV+ASV in patients with genotype 1b hepatitis C (HCV). The company also seeks approval for

OMS721 targets mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. In 2013, the company had announced that the FDA granted